Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.

Latest From Akriti Seth

Adamis Receives FDA Approval For 505(b)(2) Naloxone

Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022. 

United States Approvals

Phlow Seeks To Build On Fresenius Kabi Collaboration

US-based Phlow and Fresenius Kabi have announced an alliance to supply essential medicines, including injectables, for public health emergencies and to Children’s Hospital Coalition, a project by Phlow. In an exclusive interview with Generics Bulletin, Phlow chief business officer Dan Hackman talks about the partnership, addressing US supply chain disruptions, domestic manufacturing and more.

United States Deals

Biosimilars Forum Says 75% Market Share Could Save US Billions

The Biosimilars Forum, in partnership with the Pacific Research Institute, has released a report that shows state-by-state cost savings for the US if biosimilars were able to capture a market share of 75%. Meanwhile, the Association for Accessible Medicines has also released its complete 2021 US Generic And Biosimilar Medicines Savings Report, discouraging reducing incentives for patent challenges and early generic entry.

Biosimilars Policy

US Bill Would Create Emergency API Stockpile

US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.

United States Coronavirus COVID-19

Glenmark Launches Tiotropium DPI In Spain

India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets. 

Generic Drugs Launches

Amgen Urges Balance In US Biosimilars Policy

Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.

Biosimilars Policy
See All
UsernamePublicRestriction

Register